RE:RE:RE:RE:RE:RE:RE:RE:Clinical Trial Size in Orphan and Rare Diseases Cmon De_man, if Oncy is content on becoming a career ph2 biotech, and if they push yet another indication aside (mBC now PDAC), to pursue yet another indication (anal) then they deserve what they get...which will be dilution followed by insolvency after the mass investor exodus.